Hypogonadism Clinical Trial
Official title:
A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
This is a multicenter, Phase 3, randomized, open-label, active-comparator group, efficacy
(based on Cavg of T), and safety study in adult hypogonadal male subjects. Enrollment is
based on criteria designed to select the general population of hypogonadal men. Study drug
doses will be titrated using a dose-titration algorithm based on total T Cavg. Subjects may
be androgen treatment-naïve or washed out of prior androgen replacement therapies.
Subjects must have 2 total T levels < 300 ng/dL based on 2 blood samples obtained in the
morning (AM) on 2 separate days approximately 7 days apart.
Approximately 180 subjects will be randomly assigned to receive open-label treatment in a 3:1
ratio of oral TU to Axiron (ie, approximately 135 subjects will be randomly assigned to oral
TU and approximately 45 subjects will be randomly assigned to Axiron topical solution).
Subjects who complete the study will receive approximately 105 days of treatment. Dose
titrations will be based on the T Cavg from serial PK sampling obtained on day 21 and 56 of
treatment. Primary efficacy will be based on percentage of subjects within eugonadal range at
Visit 7.
A subset of approximately 30 subjects will participate in a cosyntropin stimulation test on
Day 1 (before administration of study drug) and Day 106 after the last 24-hour PK sample has
been drawn.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
| Terminated |
NCT02419105 -
Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors
|
Phase 3 | |
| Withdrawn |
NCT02137265 -
Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism
|
N/A | |
| Completed |
NCT02233751 -
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
|
Phase 1 | |
| Completed |
NCT02222558 -
Oral Testosterone for the Treatment of Hypogonadism in Males
|
Phase 2 | |
| Completed |
NCT01887418 -
Pharmacokinetic Study of Testosterone Enanthate
|
Phase 1/Phase 2 | |
| Terminated |
NCT01092858 -
NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
|
Phase 4 | |
| Completed |
NCT00624624 -
Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism
|
N/A | |
| Completed |
NCT00752869 -
Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement
|
Phase 4 | |
| Completed |
NCT00613288 -
Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism
|
N/A | |
| Completed |
NCT00119483 -
Older Men and Testosterone
|
N/A | |
| Completed |
NCT00838838 -
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
|
N/A | |
| Completed |
NCT00004438 -
Leuprolide in Treating Adults With Hypogonadotropism
|
N/A | |
| Withdrawn |
NCT00398034 -
Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.
|
Phase 2 | |
| Completed |
NCT02937740 -
Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™
|
Phase 4 | |
| Completed |
NCT02921386 -
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
|
Phase 2 | |
| Completed |
NCT01717768 -
Oral Testosterone for the Treatment of Hypogonadism
|
Phase 2 | |
| Terminated |
NCT01460654 -
Testosterone and Alendronate in Hypogonadal Men
|
Phase 2 | |
| Completed |
NCT00998933 -
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
|
Phase 1 | |
| Completed |
NCT00857454 -
A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations
|
Phase 3 |